Trial Profile
The effect of Rifampicin on the safety, tolerability, pharmacokinetics and absolute bioavailability of oral and intravenous apixaban in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Apixaban (Primary) ; Rifampicin
- Indications Acute coronary syndromes; Stroke; Thromboembolism; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb; Pfizer
- 21 Jan 2016 New trial record
- 09 Jan 2016 Results published in the American Journal of Cardiovascular Drugs